2007
320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras
Radojcic V, Skarica M, Murphy G, Luznik L. 320: In vivo activation of APCs with TLR ligands and tissue damage rather than amount of host APCs are critical factors that determine DLI-mediated GVL reactivity and GVHD in MHC-matched minor histocompatibility antigen (mHAg)-mismatched chimeras. Transplantation And Cellular Therapy 2007, 13: 116-117. DOI: 10.1016/j.bbmt.2006.12.325.Peer-Reviewed Original ResearchFactors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse
Durakovic N, Radojcic V, Skarica M, Bezak K, Powell J, Fuchs E, Luznik L. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood 2007, 109: 4564-4574. PMID: 17227829, PMCID: PMC1885486, DOI: 10.1182/blood-2006-09-048124.Peer-Reviewed Original ResearchConceptsDonor lymphocyte infusionDonor T cellsHost T cellsBone marrow transplantationT cellsHost chimerismHost APCsMarrow transplantationPrevious sensitizationAllogeneic bone marrow transplantationToll-like receptor ligandsGvH responseGVL reactivityLeukemia reactivityLymphocyte infusionMixed chimerismTLR ligandsHost antigensMurine modelVivo administrationCell activatorsHigh levelsAlloreactivityChimerismMHC
2006
Host Langerhans cells (LCs) can be therapeutically manipulated In vivo with imiquimod (TLR7 agonist) to augment DLI-mediated GVH and GVL reactivity
Skarica M, Radojcic V, Luznik L. Host Langerhans cells (LCs) can be therapeutically manipulated In vivo with imiquimod (TLR7 agonist) to augment DLI-mediated GVH and GVL reactivity. Transplantation And Cellular Therapy 2006, 12: 52. DOI: 10.1016/j.bbmt.2005.11.164.Peer-Reviewed Original Research